StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics cash

Cash and short-term investments held at the end of each period.

Spyre Therapeutics's cash was $1.10B at Jun 30, 2026. For fiscal 2025 it was $756.50M, up 25.4% from the year before. Over ten years it grew 36.8% a year on average. The highest annual figure on record is $756.50M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$756.50M+25.4%
FY2024Dec 31, 2024$603.10M+77.7%
FY2023Dec 31, 2023$339.30M+492.5%
FY2022Dec 31, 2022$57.26M-39.7%
FY2021Dec 31, 2021$94.97M-35.9%
FY2020Dec 31, 2020$148.12M+105.9%
FY2019Dec 31, 2019$71.95M-3.4%
FY2018Dec 31, 2018$74.50M+48.1%
FY2017Dec 31, 2017$50.30M-20.8%
FY2016Dec 31, 2016$63.50M+92.1%
FY2015Dec 31, 2015$33.06M+1163.8%
FY2014Dec 31, 2014$2.62M-43.1%
FY2013Dec 31, 2013$4.60M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.10B+108.9%
Q1 FY2026Mar 31, 2026$741.50M+31.3%
Q4 FY2025Dec 31, 2025$756.50M+25.4%
Q3 FY2025Sep 30, 2025$486.20M+17.4%
Q2 FY2025Jun 30, 2025$526.58M+23.5%
Q1 FY2025Mar 31, 2025$564.82M+16.5%
Q4 FY2024Dec 31, 2024$603.10M+77.7%
Q3 FY2024Sep 30, 2024$414.23M+103.5%
Q2 FY2024Jun 30, 2024$426.30M+81.1%
Q1 FY2024Mar 31, 2024$485.00M+1119.0%
Q4 FY2023Dec 31, 2023$339.30M+492.5%
Q3 FY2023Sep 30, 2023$203.60M+170.7%
Q2 FY2023Jun 30, 2023$235.36M+165.8%
Q1 FY2023Mar 31, 2023$39.79M-40.4%
Q4 FY2022Dec 31, 2022$57.26M-39.7%
Q3 FY2022Sep 30, 2022$75.21M-33.1%
Q2 FY2022Jun 30, 2022$88.55M-31.1%
Q1 FY2022Mar 31, 2022$66.73M-47.3%
Q4 FY2021Dec 31, 2021$94.97M-35.9%
Q3 FY2021Sep 30, 2021$112.43M-19.7%
Q2 FY2021Jun 30, 2021$128.58M-18.5%
Q1 FY2021Mar 31, 2021$126.66M+158.5%
Q4 FY2020Dec 31, 2020$148.12M+105.9%
Q3 FY2020Sep 30, 2020$139.98M+57.8%
Q2 FY2020Jun 30, 2020$157.73M+49.4%
Q1 FY2020Mar 31, 2020$48.99M-60.4%
Q4 FY2019Dec 31, 2019$71.95M-3.4%
Q3 FY2019Sep 30, 2019$88.70M+37.1%
Q2 FY2019Jun 30, 2019$105.54M+46.2%
Q1 FY2019Mar 31, 2019$123.70M+184.4%
Q4 FY2018Dec 31, 2018$74.50M+48.1%
Q3 FY2018Sep 30, 2018$64.70M+16.2%
Q2 FY2018Jun 30, 2018$72.20M+13.9%
Q1 FY2018Mar 31, 2018$43.50M-24.9%
Q4 FY2017Dec 31, 2017$50.30M-20.8%
Q3 FY2017Sep 30, 2017$55.70M-18.1%
Q2 FY2017Jun 30, 2017$63.40M–
Q1 FY2017Mar 31, 2017$57.90M–
Q4 FY2016Dec 31, 2016$63.50M–
Q3 FY2016Sep 30, 2016$68.00M–

More Spyre Therapeutics figures

See a number that looks wrong?